{
  "abstract": "Bronchiectasis is a heterogeneous disease characterised by chronic inflammation leading to irreversible airway dilatation.1 Traditionally, bronchiectasis was thought to be solely caused by neutrophilic inflammation, but recent studies have shown that approximately 20% of individuals with bronchiectasis have evidence of eosinophilic inflammation, irrespective of known eosinophilic diseases such as asthma and allergic bronchopulmonary aspergillosis (ABPA).2 This finding has generated significant interest, as it may portend that bronchiectasis in some individuals is spurred on by type 2 (T2) inflammation. However, most studies to date defined eosinophilic bronchiectasis using an elevated blood eosinophil count (BEC)≥300 cells/µL. While BEC was modestly correlated with sputum eosinophils,2 there has been a paucity of data demonstrating T2 inflammation in individuals with eosinophilic bronchiectasis.",
  "authors": [
    {
      "affiliations": [
        "University of Toronto Faculty of Medicine, Toronto, Ontario, Canada"
      ],
      "name": "Omri A Arbiv"
    },
    {
      "affiliations": [
        "Department of Medicine, University of Calgary, Calgary, Ontario, Canada",
        "Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Ontario, Canada"
      ],
      "name": "Christina S Thornton"
    }
  ],
  "title": "Granules of truth: unpacking the eosinophilic endotype in bronchiectasis",
  "uid": "58832831-f2ec-51fa-8c43-3478a8ccc7c5"
}